Rheumatoid arthritis (RA) is the prototype of the rheumatic diseases worldwide. Methotrexate (MTX) is the drug of first choice in the treatment of this disease due to its immunosuppressant effect. However, side events are present in 30% of the patients. The C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene are involved in the metabolism of MTX. Earlier studies reported an association between these polymorphisms and elevation of hepatic enzymes. We analyzed the frequencies of both polymorphisms and the presence of transaminasemia in 70 Mexican patients with rheumatic arthritis treated with MTX. The 19% (13/70) of patients had an increase in the serum level of transaminases. The A1298C polymorphism was associated with elevation of transaminases (P ¼ 0.024). The identification of MTHFR genotypes for C677T and A1298C polymorphisms could lead clinicians to identify patients in risk of elevation of transaminases, and give them an individualized treatment, as is a goal of pharmacogenetics.
Introduction
Rheumatoid arthritis (RA) is the prototype of rheumatic diseases affecting 1-2% of the worldwide population.
1 Methotrexate (MTX) is the most commonly used disease modifying antirheumatic drug prescribed for RA. 2 MTX is a structural analogue of folic acid, which inhibits dihydrofolate reductase, blocking the tetrahydrofolate regeneration, the biologically active folate cofactors. MTX also influences several steps in folate metabolism including the homocysteine (hcy)-methionine pathway by inhibition of methylenetetrahydrofolate reductase (MTHFR), which synthesizes 5-methylenetetrahydrofolate acting as the methyl donor for remethylation of hcy to methionine. [3] [4] [5] However, the side effects of MTX in RA patients are frequent (68-96%), and 10-30% of the patients have discontinued its use. 6 The increased levels of transaminases is the most frequent toxicity data experienced among patients with RA treated with MTX (RA-MTX patients).
Because of its critical importance in folate metabolism, several polymorphisms of the MTHFR gene have been studied in multiple diseases such as neural tube defects, pre-eclampsia, and cardiovascular diseases among others. [7] [8] [9] The C677T polymorphism is the most prevalent and widely studied. Their frequency is variable in different populations; being as high as 45-50% in Mexico. 7, 8 This polymorphism results in a decreased enzyme activity and hyperhomocysteinemia in the general population and is responsible for an MTHFR thermolabile variant and reduced enzyme activity. 10 Other polymorphism involved in the MTHFR activity is the A1298C, which may also affect plasma hcy levels. Heterozygosity for both polymorphisms have been related not only with reduced activity of the enzyme, but also with major concentration of total hcy in plasma and levels low of folate as homozygous patients for allelemutated 677T.
11 Several studies about this last polymorphism in the MTHFR gene and individual variation in the efficacy and toxicity to MTX have been described in different populations around the world, which gives variable results. Few studies have investigated the distribution of both polymorphisms among RA-MTX patients in populations other than Caucasians. To our knowledge, there are no studies related to this association in Mexico, despite the high frequency of C677T polymorphism among the Mexican population.
Therefore, we investigate (1) the allele distribution of C677T and A1298C in the Mexican RA-MTX patients and (2) compare the relation between C677T and A1298C polymorphisms in the RA patients with and without increase in transaminases levels.
Materials and methods
A total of 70 well-characterized patients with RA, diagnosed according to the American College of Rheumatology revised criteria 12 were included in this study. Patients were divided into two groups (cases and controls) according to the transaminases levels; both received weekly similar doses of MTX (mean±s.d., 7.5±2.5 mg per week). To determine the increase of transaminases (alanine aminotransferase and aspartate aminotransferase) values, more than twice the upper limit of the normal (480 U l À1 ) were considered. Patients were recruited from the rheumatology department of Hospital General Regional No. 110 at Instituto Mexicano del Seguro Social in Guadalajara, Mexico. All of the subjects gave their written voluntary informed consent to participate. The demographic, clinical, laboratory, and therapeutic data were documented using a structured questionnaire. The study was approved by the local Ethics and Research Committee of Hospital de Especialidades at Instituto Mexicano del Seguro Social. DNA was obtained from peripheral blood leukocytes by standard methods. 13, 14 The MTHFR C677T and A1298C polymorphisms were analyzed by PCR-RFLP, with HinfI and MboII, respectively, as reported earlier.
10,15 DNA fragments were separated by PolyAcrylamide Gel Electrophoresis. The restriction patterns were analyzed by electrophoresis on polyacrylamide gels in 6% (29:1) and 12% (19:1) for C677T and A1298C, respectively. 16 
Statistical analysis
Allele and genotype frequencies for each locus were estimated by the gene counting method. The differences in the allele and genotype distributions between both the groups (with and without transaminasemia) were evaluated using the w 2 test with the TFPGA program and MantelHaenszel test. 17 The De Finneti software was used to assess the association. 18 Significance levels for each exact test were assessed by 95% confidence intervals.
Results
The 19% (13/70) of patients had increased transaminases serum levels. Table 1 shows the allele and genotype frequencies among both the groups; RA-MTX patients with increase serum levels of transaminases (cases) and RA-MTX patients without (controls) for MTHFR C677T and A1298C. There were no significant differences in allele and genotype frequencies of C677T between cases and controls. The 1298C allele frequency was 42% in cases and 21% in control group according to the De Finneti program (P ¼ 0.024, odds ratio ¼ 2.7, confidence interval ¼ 1.11-6.75) and confirmed by Mantel-Haenszel test (P ¼ 0.024, odds ratio ¼ 2.75, confidence interval ¼ 1.02-7.40). Table 2 shows the analysis of association in RA-MTX patients with and without transaminasemia. The dominant model showed that 1298C allele presented dominant characteristics (AC þ CC vs AA, P ¼ 0.045, odds ratio ¼ 3.5, confidence interval ¼ 0.98-13.04) ( Table 2 ). The 69% (9/13) of RA-MTX patients with increased serum levels of transaminases carried at least one 1298C allele, whereas in groups without transaminasemia, only 38% were 1298C allele carriers. The distribution of the combined genotypes is shown in Table 3 . To determine whether the MTHFR C677T and A1298C polymorphisms exert a genetic additive effect on transaminasemia in RA-MTX patients, we analyzed the combined genotypes. As the CT/CC and TT/CC genotype combinations were zero, they were excluded from the analysis. The most frequent genotype combination in the case group was double heterozygous CT/AC (38.4%). The 85% (11/13) had at least one mutated allele for any of the studied polymorphisms.
Discussion
The main findings of this study was the high frequency of 1298C allele in case group (42%, 11/26 alleles) vs controls (21%, 24/114 alleles). The heterozygosity for A1298C in cases group was significantly higher than control group, 54% (7/13) vs 35% (20/57). The association studies of C677T and A1298C polymorphisms in the MTHFR gene and individual variation in the efficacy and/or toxicity to MTX in patients with RA have controversial results in different populations. 6, 11, [19] [20] [21] [22] Some groups have reported association between MTHFR-C677T polymorphism and toxicity to MTX in Dutch and Japanese population for one or the other allele. In some populations, the 1298CC genotype is considered as protective against adverse effects or efficacy. Our results indicate that the C677T polymorphism has no association with toxicity for any allele or genotype. Regarding A1298C polymorphism, our study is in agreement with earlier report. Wessels et al. reported that the patients with 1298C allele had more side effects in RA Dutch patients. 11 In contrast, in Afro-American and Caucasians, they did not find association. 6 In our study, the association test showed that 1298C allele presented dominant characteristics ( Table 2 ). The most frequent genotype combination in RA patients with transaminasemia was the double heterozygous state (CT/AC). The heterozygous state shows reduced activity of the enzyme (50-60% of healthy), major concentration of total hcy in plasma and low levels of folate is shown in homozygous patients for allele 677T. 21 These results suggest that the double heterozygous status could have an additive genetic effect on transaminasemia. A limitation of this study is the relative small number of cases; to minimize it, we included three controls for each case. Although we should note that it is an exploratory study showing a trend to a higher frequency as possible genetic risk factor (1298C allele), it is necessary to carry out further studies by increasing the number of patients. The differences in the results of these polymorphisms and their association with transaminasemia should be related to ethnic background as well as racial/ethnic differences. In summary, our findings suggest that the polymorphism A1298C is significantly associated to transaminasemia due to MTX in RA patients of Mexican population. The C677T polymorphism was not associated. The identification of MTHFR genotypes for A1298C polymorphism and genotype combination C677T and A1298C could lead to identify the patients in risk of elevation of transaminasemia in RA-MTX patients and permit a more individualized treatment, and may predict the particular response to therapy and vigilance to potential side effects, as is the objective of pharmacogenetics. 
